Tags

Type your tag names separated by a space and hit enter

Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
Vaccine. 2010 Aug 31; 28(38):6159-63.V

Abstract

We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30 microg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer >or=1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30 microg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30 microg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30 microg, respectively. This study indicated that one dose of 15 microg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively).

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kao TM
Department of Internal Medicine, National Taiwan University Hospital, Medical College of National Taiwan University, Taipei, Taiwan.
Hsieh SM
No affiliation info available
Kung HC
No affiliation info available
Lee YC
No affiliation info available
Huang KC
No affiliation info available
Huang LM
No affiliation info available
Chang FY
No affiliation info available
Wang NC
No affiliation info available
Liu YC
No affiliation info available
Lee WS
No affiliation info available
Liu HE
No affiliation info available
Chen CI
No affiliation info available
Chen CH
No affiliation info available

MeSH

Age FactorsAgedAged, 80 and overAntibodies, ViralAntibody FormationDiabetes MellitusFemaleHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesInfluenza, HumanLogistic ModelsMaleMiddle AgedMultivariate AnalysisSex FactorsSingle-Blind MethodTaiwan

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20659517

Clinical Trial Links

Clinical trial which this article describes

Citation

Kao, Tsui Mai, et al. "Immune Response of Single Dose Vaccination Against 2009 Pandemic Influenza a (H1N1) in the Taiwanese Elderly." Vaccine, vol. 28, no. 38, 2010, pp. 6159-63.
Kao TM, Hsieh SM, Kung HC, et al. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine. 2010;28(38):6159-63.
Kao, T. M., Hsieh, S. M., Kung, H. C., Lee, Y. C., Huang, K. C., Huang, L. M., Chang, F. Y., Wang, N. C., Liu, Y. C., Lee, W. S., Liu, H. E., Chen, C. I., & Chen, C. H. (2010). Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine, 28(38), 6159-63. https://doi.org/10.1016/j.vaccine.2010.07.026
Kao TM, et al. Immune Response of Single Dose Vaccination Against 2009 Pandemic Influenza a (H1N1) in the Taiwanese Elderly. Vaccine. 2010 Aug 31;28(38):6159-63. PubMed PMID: 20659517.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. AU - Kao,Tsui Mai, AU - Hsieh,Szu Min, AU - Kung,Hsiang Chi, AU - Lee,Yi Chien, AU - Huang,Kuo Chin, AU - Huang,Li Min, AU - Chang,Feng Yee, AU - Wang,Ning Chi, AU - Liu,Yung Ching, AU - Lee,Wen Sen, AU - Liu,Hsingjin Eugene, AU - Chen,Chin I, AU - Chen,Chien-Hui, Y1 - 2010/07/24/ PY - 2010/02/05/received PY - 2010/06/27/revised PY - 2010/07/12/accepted PY - 2010/7/28/entrez PY - 2010/7/28/pubmed PY - 2010/10/30/medline SP - 6159 EP - 63 JF - Vaccine JO - Vaccine VL - 28 IS - 38 N2 - We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30 microg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer >or=1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30 microg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30 microg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30 microg, respectively. This study indicated that one dose of 15 microg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively). SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20659517/Immune_response_of_single_dose_vaccination_against_2009_pandemic_influenza_A__H1N1__in_the_Taiwanese_elderly_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01021-2 DB - PRIME DP - Unbound Medicine ER -